Immuron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Immuron and other ETFs, options, and stocks.

About IMRN

Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. It operates through the Hyper-immune Products and Research and Development (R&D) segments. 

CEO
Steven Lydeamore
CEOSteven Lydeamore
Employees
Employees
Headquarters
Blackburn, Victoria (VIC)
HeadquartersBlackburn, Victoria (VIC)
Founded
1994
Founded1994
Employees
Employees

IMRN Key Statistics

Market cap
9.12M
Market cap9.12M
Price-Earnings ratio
-2.35
Price-Earnings ratio-2.35
Dividend yield
Dividend yield
Average volume
64.68K
Average volume64.68K
High today
$1.18
High today$1.18
Low today
$1.12
Low today$1.12
Open price
$1.21
Open price$1.21
Volume
3.58K
Volume3.58K
52 Week high
$2.39
52 Week high$2.39
52 Week low
$0.6765
52 Week low$0.6765

IMRN News

TipRanks 2h
Immuron CEO to Present TechKnow Invest Roadshow in Melbourne

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

TipRanks 23h
Immuron Showcases Oral Antibody Platform in July 20 Investor Presentation - TipRanks

...

Immuron Showcases Oral Antibody Platform in July 20 Investor Presentation - TipRanks

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.